Merck KGaA Just Paid $1.3 Billion to Silence a Gene
Merck KGaA is dropping $1.3 billion to buy Silence Therapeutics, a gene-silencing biotech with a rare blood cancer drug that crushed its Phase 2 trial. The deal signals big pharma's growing obsession with owning siRNA platforms, not just licensing them.
You know that friend who quietly builds the best fantasy team while everyone else is making splashy trades? That's been Merck KGaA for the past two years. While the pharma world obsessed over GLP-1s and AI drug discovery, the German giant was methodically assembling a rare disease empire.
Now it's making its loudest move yet: a $1.3 billion all-cash deal to buy Silence Therapeutics, a London-based biotech that specializes in shutting genes off.
The Deal at a Glance
Merck KGaA is paying $20.00 per American Depositary Share, which works out to roughly $6.67 per ordinary share. That's a 130% premium over Silence's closing price on October 16, 2026. Even measured against the 30-day volume-weighted average price, the premium clocks in at 82%.
In biotech M&A terms, that's not just knocking on the door. That's kicking it down and rearranging the furniture.
The deal values Silence at about $1.3 billion in equity and roughly $1.1 billion in enterprise value. It's structured as a U.K. scheme of arrangement (a British legal mechanism for acquisitions), and it needs shareholder approval plus a High Court blessing in England and Wales. If everything goes smoothly, Merck expects to close in the first quarter of 2027.
What Merck Is Actually Buying
Let's talk about the crown jewel: divesiran.
Divesiran is an siRNA therapy, which stands for "small interfering RNA." Think of it like a molecular sniper. Your DNA makes RNA, and RNA makes proteins. Some of those proteins cause disease. siRNA finds the specific RNA messenger responsible and destroys it before it can do its job. No messenger, no harmful protein. Problem (potentially) solved.
Divesiran's target is a protein called TMPRSS6, and the disease it's aimed at is polycythemia vera, a rare blood cancer where the body overproduces red blood cells. Patients with PV often need regular phlebotomies (essentially therapeutic blood draws, like donating blood except nobody asked you to) to keep their blood from getting dangerously thick.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Phase 2 results were, frankly, stellar. In the SANRECO trial, 88% of patients on divesiran met the primary response criteria. The placebo group? Just 19%. The p-value was less than 0.0001, which in statistics-speak means "this almost certainly wasn't a fluke."
The secondary endpoints told an equally compelling story. Patients on divesiran needed an average of 0.2 phlebotomies during the study period. Placebo patients needed 2.1. Researchers also saw improvements in hematocrit control, iron markers like ferritin, and patient-reported symptoms.
On safety, divesiran was well tolerated. Injection-site reactions were infrequent and resolved on their own. Investigators reported only two grade 1 anemia events and zero treatment-related serious adverse events. Nobody dropped out because of side effects.
One important caveat: divesiran hasn't completed a Phase 3 trial yet. It's described as "Phase 3-ready," which means the data looks great but the most expensive, most rigorous test is still ahead. Merck is essentially buying a lottery ticket where most of the numbers have already matched.
More Than One Bullet in the Chamber
Divesiran gets the headlines, but Silence's pipeline is deeper than a single program. Merck is buying an entire siRNA platform called mRNAi GOLD, along with several other candidates at various stages.
Zerlasiran is the next most advanced internal asset. It targets a protein called Lp(a), a cardiovascular risk factor that's notoriously difficult to treat with traditional medicines. Zerlasiran was in the Phase 2 to Phase 3 transition as of 2026, making it another potentially valuable piece of the puzzle.
Then there's SLN312, an siRNA targeting ANGPTL3 for dyslipidemia (high cholesterol, essentially). This one is already partnered with AstraZeneca, which means Merck inherits a collaboration with one of the world's largest pharma companies.
Behind those sit two preclinical programs: SLN365 for a rare cholesterol condition and SLN098 for obesity. Plus SLN548, which targets the complement pathway (a part of the immune system involved in inflammation) and was heading into Phase 1.
So Merck isn't just buying a drug. It's buying a factory that makes drugs, with several already partway down the assembly line.
Why Merck KGaA, and Why Now?
This acquisition didn't come out of nowhere. Merck KGaA has been telegraphing its rare disease ambitions for at least two years.
The company has emphasized in recent communications that external deals would play a major role in its future launches. That's a remarkable signal for a company with its own research labs. It's basically saying: "We're better at picking winners than growing them from scratch."
In 2025, Merck acquired SpringWorks Therapeutics, doubling down on rare disease. It initiated Phase 3 trials for bomedemstat in essential thrombocythemia and nemtabrutinib in chronic lymphocytic leukemia.
The Silence deal is the next logical step. Merck was already building a hematology franchise through traditional small molecules and antibody-drug conjugates. Now it's adding RNA interference to its toolkit, a completely different modality that could open doors to diseases where conventional drugs struggle.
It's like a basketball team that already has great shooters deciding to add an elite defender. Different skill, same goal: winning.
The Bigger Picture: RNAi's M&A Moment
Merck KGaA isn't the only big pharma company writing checks for siRNA technology. The RNAi space has been on fire.
In 2025 alone, Novartis reportedly struck a collaboration worth up to $2.2 billion involving siRNA assets. Bristol-Myers Squibb paid $1.5 billion for Orbital Therapeutics. Nature reported that siRNA and ASO (antisense oligonucleotide) assets still command the highest upfront payments of any RNA modality.
The commercial proof point already exists: Alnylam Pharmaceuticals has a marketed siRNA franchise and remains the gold standard for the technology. But as the field matures, big pharma companies want to own their own platforms rather than keep licensing individual programs.
One 2025 analysis found that RNAi rare-disease acquisitions had a median upfront of $275 million at Phase 2, with total deal values stretching above $1 billion. The Silence deal, at $1.3 billion for a Phase 3-ready lead asset plus a multi-program pipeline, fits squarely within that range.
What makes rare disease particularly attractive for siRNA buyers is the math. Orphan drug pricing can support smaller patient populations. Infrequent dosing (divesiran was tested at every 6 or 12 weeks) reduces the burden on patients and health systems. And if you own the platform, every new target you validate makes the next program cheaper to develop.
Is the Price Right?
A 130% premium sounds aggressive. But context matters.
Silence Therapeutics had been trading at depressed levels, which makes the percentage premium look more dramatic than the absolute valuation might suggest. At $1.1 billion in enterprise value, Merck is paying for a late-stage rare disease asset with clean Phase 2 data, a cardiovascular program approaching Phase 3, an AstraZeneca partnership, and a proprietary siRNA platform with multiple early-stage shots on goal.
Analysts and industry commentators have framed the deal as "full but defensible." The logic: Silence has scarcity value. There aren't many independent siRNA companies left with this combination of clinical maturity and platform breadth. When something is scarce and strategically valuable, you pay up or you lose it.
The biggest risk is straightforward. Divesiran still needs to run (and pass) a Phase 3 trial. Phase 2 results in rare diseases are generally more predictive than in broader indications, but nothing is guaranteed until the pivotal data reads out. Merck is betting that an 88% response rate with a stellar safety profile will hold up in a larger, longer study.
What Happens Next
Silence shareholders will vote on the deal. The U.K. High Court will need to sanction it. Regulatory authorities in relevant jurisdictions will review it. Assuming no surprises, the transaction should close in Q1 2027.
After that, the real work begins. Merck will need to design and execute a Phase 3 trial for divesiran, advance zerlasiran into late-stage cardiovascular studies, and figure out how to integrate Silence's platform into its broader R&D organization.
For polycythemia vera patients, the deal is probably good news. Having a large pharma company with deep pockets behind divesiran means the Phase 3 program is more likely to be well-funded and efficiently run. For the broader RNAi field, this acquisition is another data point confirming that big pharma sees gene silencing not as a niche curiosity, but as a core therapeutic modality worth billions.
Merck KGaA just made its bet. Now it has to prove the silence is worth $1.3 billion.
Clinical & Regulatory
4 min read
EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips.
EyePoint Pharmaceuticals failed its second Phase 3 wet AMD trial in two months, triggering an 85% stock crash and layoffs for more than half its workforce. The double miss is the latest cautionary tale in a sector that punishes clinical ambiguity with existential consequences.
